Safety Concerns Halt Merck & Co’s Once-Weekly HIV Combination

Blow For Company’s HIV Strategy

 
• By Andrew McConaghie
  
Merck
Merck's goal of competing in a new generation of longer-acting HIV therapies could be hit by the safety setback. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D